Top 20 global biopharma firms see 1.7 per cent market cap growth to $3.7 billion in 2024 amid policy challenges Read more
Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise Lenacapavir Read more
Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis market Read more
